This program provides an advanced oncological framework for managing Chronic Myeloid Leukemia (CML) following treatment failure or intolerance to frontline tyrosine kinase inhibitors (TKIs). Clinicians will explore the mechanisms of acquired resistance—such as specific kinase domain mutations—and how they dictate optimal second- and third-line TKI selection. The curriculum emphasizes personalized treatment sequencing, robust mutation testing protocols, and the integration of emerging therapeutic classes to maximize molecular response and long-term survival.